Table 1 Demographic and clinical characteristics of the two groups
Bilateral nerve-sparing RARP (n = 46) | Unilateral nerve-sparing RARP (n = 137) | |||||
|---|---|---|---|---|---|---|
With HA/CMC (n = 13) | Without HA/CMC (n = 33) | P value | With HA/CMC (n = 40) | Without HA/CMC (n = 97) | P value | |
Age | 64.0 (54.1–67.2) | 64.9 (59.5–71.3) | 0.18 | 66.4 (62.5–70.7) | 66.0 (63.0–71.0) | 0.99 |
BMI | 23.5 (21.3–24.4) | 23.1 (21.5–25.5) | 0.55 | 23.6 (21.5–25.0) | 23.4 (21.6–25.1) | 0.14 |
Pretreatment PSA | 7.7 (6.0–9.2) | 7.2 (5.5–11.5) | 0.87 | 7.6 (5.2–10.1) | 7.2 (5.3–9.6) | 0.63 |
Prostate volume (cm2) | 24.5 (14–42.8) | 28.0 (20.0–45.5) | 0.26 | 28.0 (20.0–32.3) | 25.0 (20.0–34.8) | 0.82 |
Clinical stage | 0.74 | 0.65 | ||||
cT1c | 6 (46.2) | 16 (48.5) | 8 (20.0) | 18 (18.6) | ||
≥cT2 | 7 (53.8) | 17 (51.5) | 32 (80.0) | 79 (81.4) | ||
Gleason sum | 6 (6–6.5) | 7 (6–7) | 0.32 | 7 (7–8) | 7 (6.5–7) | 0.13 |
Charlson comorbidity index, n (%) | 0.68 | 0.43 | ||||
0 | 3 (23.1) | 9 (27.3) | 11 (27.5) | 32 (33.0) | ||
≥1 | 10 (76.9) | 24 (72.7) | 29 (72.5) | 65 (67.0) | ||
Institutional caseload> 200, n (%) | 10 (76.9) | 16 (48.5) | 0.08 | 30 (75.0) | 57 (57.7) | 0.06 |